A retrospective population pharmacokinetic (PPK) analysis was performed in 24 pediatric patients (PEDS) (0.45-16.7 years old) receiving i.v. busulfan/cyclophosphamide (i.v. Bu/Cy 4) regimen prior to allogeneic hematopoietic stem cell transplantation. I.V. Bu doses were given as a 2-hour infusion every 6 h over 4 days. Initial dosing of i.v. Bu was 1 mg/kg for children p4 years old and 0.8 mg/kg for patients 44 years old. Bu plasma concentrations at doses 1, 9 and 13 were analyzed through a multivariate NONMEM analysis. A close log-linear relationship between body weight (BW) and i.v. Bu clearance was demonstrated with no further age-dependency or gender effect. The interpatient coefficient of variation (CV) in Bu clearance significantly decreased from 56% (covariate-free model) to 19% (BW covariate model) and reproducible i.v. Bu exposure between doses was illustrated (intraindividual CV ¼ 9%). Based on the PPK model, a novel Bu dosing regimen (ie: doses in mg/kg adjusted to discrete weight categories) for a better AUC targeting was developed by simulation on 1000 patients. Age-based dosing was demonstrated not to be clinically relevant with i.v. Bu. Use of the new BW-based dosing appears to be more appropriate for the PEDS.
busulfan;
pediatrics; population pharmacokinetics A high dose of busulfan (Bu) in combination with cyclophosphamide (Cy) is a widely used conditioning regimen in adults and children for allogeneic and autologous bone marrow transplant (BMT) for both malignant and nonmalignant diseases. The standard Bu/Cy pretransplant regimen for pediatric patients (PEDS) consists of Bu administered every 6 h over 4 days at a dose of 1 mg/kg followed by Cy administered intravenously (i.v.) as a single dose of 50 mg/kg over 4 days (Bu/Cy4). 1 Until recently, the nonavailability of an intravenous Bu formulation required that Bu be administered orally -a nonoptimal route for the pediatric population.
Bu pharmacokinetic (PK) variability following oral administration is well documented in PEDS. The interpatient bioavailability in children was shown to vary as much as five-fold 2 and a six-to twenty-fold variation in apparent clearance (Cl tot /F) was observed. [3] [4] [5] [6] Significant interdose variability is also described in a number of studies. [7] [8] [9] [10] This high variability in oral Bu PK behavior is known to affect the safety and the therapeutic outcomes of Bu-based conditioning regimens. Failing to control the systemic exposure over the course of treatment is associated with a higher risk of regimen-related toxicities (RRT), significant morbidity and reduced efficacy: high Bu exposure correlates with the increased frequency of hepatic complications, especially veno-occlusive disease (VOD). [11] [12] [13] [14] The risk of VOD appears to be related to a Bu systemic exposure higher than 1500 mM min. This threshold toxic limit for VOD has been primarily demonstrated in adults. 12, 15 In contrast, no threshold limit for hepatic toxicity has been evidenced in pediatrics yet and a standard value remains to be defined.
Pediatric literature studies have been conducted under various conditions and several factors are invoked to explain the absence of a clear relationship in PEDS between Bu exposure and severe RRT such as VOD. A low occurrence of severe VOD in PEDS studies is often observed and precludes any powerful PK/PD analysis. The relationship between VOD and Bu exposure is also thought to be disease-specific (patients with CML tolerate higher Bu exposure) or related to the nature of conditioning regimen (number, dose level and type of alkylating agents combined with Bu). In the Bu/Cy preparative regimen, Cy, and more specifically its hepatotoxic metabolite, hydroxycyclophosphamide, may contribute towards the occurrence of VOD. 16, 17 Since a higher dose of Cy is usually administered to PEDS than to adults (200 vs 120 mg/kg), the well-established relationship in adults between Bu exposure and VOD could be obscured in PEDS. 18, 19 To date, the only existing threshold Bu exposure for VOD has been defined at 1500 mM min, although demonstrated in adults only.
In contrast, literature data agree to define a threshold value of AUC improving graft retention for both adults and children. A Bu systemic exposure higher than 900 mM min is commonly reported to decrease the risk of graft rejection. [11] [12] [13] [14] [15] 18, 19 Age-related changes in PK are thought to explain the wide variability in children and the differences in drug clearance between adults and children. Some studies have demonstrated an age-Bu clearance dependency even if corrected by body size indices. 7, 11, [20] [21] [22] An age close to 4 years old seems to be the threshold value to split PEDS into two subgroups: a higher oral Bu clearance in children p4 years requires administration of a higher dose than in patients 44 years old. 23, 24 The reasons for these differences have not been clearly identified but may be related to higher intestinal and/or hepatic metabolism after oral administration in younger children. 23, 24 Dosing Bu based on body surface area (BSA) has been proposed to eliminate the difference in Bu exposure between adults and children, but still demonstrates a wide interindividual variability in drug exposure. 9, 25, 26 Therefore, the extent to which PK parameters normalized to body size vary as a function of age remains unclear and appropriate oral dosing strategy is still challenging in PEDS.
Subsequently, AUC guided dose adjustment was suggested to optimize the oral Bu dose for higher therapeutic efficacy and lower RRT. [8] [9] [10] 14, 18, 27 Therapeutic drug monitoring is intended to reduce the high variation in plasma exposure following oral administration. However, this strategy is not accessible to all investigator centers and is seldom implemented in clinical settings because blood collection and samples handling call for specific laboratory equipment, prompt analysis using a reliable and rapid assay method for plasma drug determination as well as skilled nursing staff. Moreover, the attempt to individualize oral Bu dosing based on concentration monitoring could be jeopardized by multiple problems inherent to the use of the oral form. These include vomiting, slow, incomplete and erratic absorption, and unpredictable bioavailability between administrations. Such problems have challenged the value of PK monitoring to individualize oral Bu dosing and prompted the development of an i.v. formulation. The i.v. form of Bu was designed to provide complete availability of the dose, to reduce the variability of the oral formulation and therefore to improve safety/clinical benefit of Bu-based regimen.
An i.v. formulation of Bu solubilized in dimethylacetamide and PEG-400 excipients has been developed and registered in the USA (Busulfext) for adults with dosing recommendation for pediatric use. The same formulation has been recently approved in Europe (Busilvex s ) for adult use. A 2-hour infusion for the administration of i.v. Bu was chosen to mimic a typical Bu PK profile following oral dosing. The reduced variability of i.v. Bu should be a major benefit in PEDS who exhibit increased PK variability as compared with adults.
To evaluate the PK of i.v. Bu in PEDS, a clinical trial was carried out in 24 children undergoing allogeneic hematopoietic progenitor cell transplantation (HPCT) and receiving i.v. Bu/Cy4 regimen. Initial doses of i.v. Bu were those commonly used for oral Bu in pediatrics, defining two age-dependent dosing: 1 mg/kg for patients p4 years and 0.8 mg/kg for patients 44 years.
A retrospective analysis of this pediatric trial data suggested a moderate increase of i.v. Bu clearance in the youngest patients (p4 years old), but this was not clearly demonstrated. Therefore, the validity of an age-based doseadaptative regimen was questioned. A critical issue in administering i.v. Bu in children was whether the variability in clearance could be only explained by body size or was further dependent on age. To address this issue, a retrospective population pharmacokinetic (PPK) analysis combined with validation and simulation techniques was performed. PPK analysis allows multivariate investigation of the impact of covariates such as body size indices, gender and age, as well as the exploration of nonlinear relationships between PK parameters and covariates. To compensate the study's limited sample size (n ¼ 24 patients), a simulated large database (1000 patients) allowed assessment of the ability of different dosing schedules to achieve the defined target exposure.
We report here the results of the population analysis and simulations. The aims of this analysis were: to assess the magnitude of inter-and intrapatient variabilities, to investigate the impact of the demographic covariates on the i.v. Bu PK and especially to elucidate the respective influence of body size and age on the clearance of i.v. Bu, to improve the former dosing schedule based upon an empirical cutoff age of 4 years and to optimize pediatric dosing guidelines when using i.v. Bu/Cy conditioning regimen prior to HPCT.
Materials and methods

Patients and dosing schedule
A total of 24 PEDS (aged from 0.45 to 16.7 years old) were enrolled in a phase II clinical trial conducted from November 1997 to January 2000. This clinical trial was intended to evaluate the safety, efficacy and PK of i.v. Bu in PEDS. A total of 10 centers, located in USA, participated in this study, which had been approved by the affiliated study center Institutional Review Boards.
Each patient received a standard 16-dose regimen of i.v. Bu administered every 6 h over 4 days and followed by Cy administered once daily (50 mg/kg) over 4 days as preparation prior to allogeneic bone marrow or blood progenitor cell transplantation. The i.v. Bu dose was prepared in 5% dextrose in water or normal saline and administered by slow i.v. infusion over 2 h into a central venous catheter.
An infusion pump was used and infusion sets had minimal priming space (0.3-0.6 ml) and were prefilled with the drug prior to start of infusion. Morning doses were given as close as possible to 08.00. The planned initial dose of i.v. Bu was based on both the age group and the actual body weight (ABW): 1 mg/kg for patients p4 years of age and 0.8 mg/kg for patients 44 years of age. In order to achieve a mean exposure of 1125 mM min, a single dose adjustment was allowed and continued for all subsequent doses of i.v. Bu. After a review of the PK at the first dose, patients were dose adjusted if their exposure was found to be beyond the AUC area (5% of 900-1350 mM min). PKs were also evaluated at the ninth dose to assess if the desired AUC had been achieved. The average i.v. Bu dose per administration for dose 1 was 0.89 mg/kg (0.97 and 0.81 mg/kg for the patients below and over 4 years old, respectively). Nine patients (five out of 13 p4 years and four out of 11 44 years) had a single dose adjustment (either after dose 5 or 9). Of these nine patients, seven patients required a dose increase (from 0.90 up to 1.59 mg/kg) and two patients had a dose decrease (0.54 and 0.79 mg/kg). The final (after dose adjustment) average dose of i.v. Bu per administration was 1.01 mg/kg (1.10 mg/kg for patients p4 years old and 0.90 mg/kg for patients 44 years old).
In order to prevent seizure caused by Bu, phenytoin was administered to 23 patients and fosphenytoin was administered to one patient. Antiseizure prophylaxis started the day before initiating Bu therapy and doses were adjusted to keep the total plasma phenytoin concentrations in the therapeutic range (10-20 mg/l).
Sampling and Bu determination
PK samples were obtained at doses 1, 9 and 13.
For doses 1 and 9, blood samples were collected through a peripheral i.v. line at pre-infusion, and at 0.25, 0.5, 0.75, 1.92, 2.25, 2.5, 3.0, 4.0 and 6.0 h after the start of infusion. For dose 13, two samples were obtained: preinfusion and immediately after the end of the infusion, respectively.
After collection, blood samples were centrifuged and plasma was stored at -201C until analysis. Bu plasma concentrations were determined using a gas chromatographymass spectrometry (GC-MS) method that had a limit of quantitation of 62.5 ng/ml. The within-run and betweenrun coefficients of variation were always below 10%.
PK analysis
Determination of the best PK model describing the concentration-time profile of i.v. Bu was performed by Nonlinear Mixed Effect modeling, using the first order with conditional estimation (FOCE) and interaction method within the NONMEM program (version V.0). 28 First, a covariate-free PK model (basic model) was developed to quantify both inter-and intrapatient (interoccasion) variabilities. A one-or a two-compartment model with zero-order input and first-order elimination was assessed. The influence of the following demographic covariates: age, height (HT), BSA, ABW and gender was investigated on clearance (Cl tot ) and volume of distribution (Vc).
Since demographic covariates were likely to be highly correlated between each other, the impact of covariates on PK parameters was first screened by univariate NONMEM analysis: each covariate was introduced once at the time into the model in terms of linear and nonlinear relationships. Different body size-based models such as power function model 29 or log-linear equations were tried.
The respective influence of a covariate along with the shape of its relationships with the PK parameter was judged in terms of improvement of fit, precision of the model parameters and its ability to explain the interpatient variability. The model building process was also guided by graphical evaluation plotting individual PK parameters vs each covariate.
In the second step, covariates were added cumulatively into the model; first, the covariates showing the highest influence during the screening step and then those less significantly correlated. For hierarchical models, a drop in the objective function value (OFV) produced by NON-MEM, which is a 'goodness of fit' statistic, by more than 3.84 denotes an improved fit at po0.05. The process of covariate inclusion into the model was stopped when there was no longer a significant improvement of fit.
Model validation
The final model was assessed using a bootstrap procedure. 30 One thousand bootstrap samples of 24 subjects were generated by repeated random sampling with replacement from the original dataset. Then, parameters of the final model were re-estimated with NONMEM modeling on each of the bootstrapped samples. Finally, model parameters distributions (mean, 95% confidence interval and CV precision) computed from the 1000 samples were compared to that obtained from the original dataset.
The model was considered stable if the model parameters obtained from the original dataset were included in the 95% confidence interval calculated from the 1000 samples.
Dosing simulations
Based on the final population model, a new dosage nomogram was defined in order to achieve a mean AUC at 1125 mM min. This new dosage was compared with standard dosing strategies using a large simulated dataset of 1000 patients. To this end, 1000 clearance values were generated in NONMEM along with the variabilities estimated from the final population model and the patient weights were simulated according to a uniform distribution, from 5 to 50 kg.
The standard dosing strategies implemented in the simulation consisted in single fixed doses based either on ABW or BSA normalization and the former age-based dosing used in the pediatric trial. Simulated BSA-based doses were calculated using the ABW only according to the Boyd formula for PEDS. 31 Then, AUC according to each dosing strategy were calculated as dose divided by the individual patient's clearance generated by NONMEM.
Variability in AUC, expressed by the coefficient of variation (CV) and the ratio between minimum and maximum values, was compared between dosing strategies. The percentages of patients within the (900-1500 mM min) range of AUC were also compared. The best dosing strategy was the one with both the lower variability in AUC and the highest rate of success in achieving the targeted AUC window.
Results
Data
The concentration vs time data are presented in Figure 1 . A total of 502 plasma concentrations collected from 70 administrations (taking into account doses 1, 9 and 13) were available for analysis purpose.
In total, 15 patients (62%) had malignant diseases and nine patients (38%) had nonmalignant diseases. In all, 16 (67%) patients had prior chemotherapy regimens, five (21%) had prior radiation treatment, six (25%) had prior surgery and one patient had undergone prior BMT. Demographic and disease characteristics of the patients are reported in Table 1 .
PK analysis
A one-compartment model was found to describe the concentration-time data suitably. A two-compartment model improved the fit of the data although leading to unacceptable precision (standard error 450%) and inconsistencies in model parameters.
Using an exponential error model, interindividual variability (IIV) was estimated on all PK parameters, and interoccasion variability (IOV) could be estimated on clearance only. Residual variability was best modeled using a combined proportional plus additive error model. Parameters of the basic model are reported in Table 2 .
All the demographic covariates were highly correlated with both Vc and Cl tot , but the best relationships were obtained by using nonlinear function between body size covariates (ie: ABW or BSA) and PK parameters.
Vc was a power function of ABW: Vc ¼ y 4 :ABW
where y 4 and y 3 represent the intercept and the slope of the model, respectively. For the i.v. Bu, the intercept was not different from 1 and the slope was 0.85. Consequently, the equation could be simplified as follows: Vc ¼ ABW y 3 . Covariate screening for the i.v. Bu clearance is presented in Table 3 .
The highest reduction in interindividual variability was found when Cl tot was related with either BSA or ABW using a log-linear function. Both body sizes yielded similar OFV and the highest drop in OFV (D ¼ À86) as compared to the other tested relationships. Model development was carried out using the ABW covariate:
No further significant improvement of fit resulted when either HT, BSA, gender or age were introduced into the model, including ABW correlated with both Cl tot and Vc. Therefore, the final model selected ABW as the only covariate to be influential on the PK of i.v. Bu.
The final model illustrated consistency through the bootstrap validation procedure: there was no difference between the mean parameters obtained from the 1000 bootstrapped samples and those obtained from the original dataset ( Table 2) .
The introduction of ABW in the model resulted in a large decrease in PK interindividual variability ( Table 2 ). The interindividual CV was reduced from 56 and 61 (basic model) to 19 and 12% (final model) for i.v. Bu clearance and volume of distribution, respectively. This large decrease in variability is graphically illustrated by the improvement of fit between the observed and the modelpredicted concentrations from the basic to the final model ( Figure 2 ).
New dosing strategy and simulations
Since the clearance of i.v. Bu was demonstrated to be a loglinear function of ABW, the total doses should also be a log-linear function of ABW.
Based on this conclusion, a log-linear relationship between the total doses and ABW was generated to achieve a target AUC of 1125 mM min and is illustrated in Figure 3 (upper graph). This log-linear curve dosing would be difficult to use in clinical practice and because pediatricians are more familiar with body size-based dosing, a nomogram of weight categories was derived. To this end, the loglinear curve was transformed by dividing the total dose by the patient BW. This produced a kind of bell-shaped relationships between dose expressed in mg/kg and ABW (lower graph in Figure 3) . Five dosages were then defined according to selected weight categories in order to be as close as possible to the continuous dosing curve. The five fixed doses resulted in an original optimal nomogram as shown in Table 4 . The results of the simulations based on a sample of 1000 patients are presented in Table 5 and Figure 4 .
The ability to target the patient AUC was better for the new dosage compared to all other standard dosing strategies. The CV in AUC was lower for the new dosage (CV ¼ 26%) compared to that obtained with the other strategies (CV from 29 to 36%). Particularly high AUC values, ranging from 4286 to 6429 mM min, were observed for the BSA based dosing with a 8.5-fold variation between minimum and maximum values (Table 5) . Pooling all weight groups (n ¼ 1000 patients), the percentage of patients within the target AUC window was about 75% for the new dosage while ranging from 45 to 69% for the other dosing strategies. As shown in Figure 4 , the success rate was calculated between equal ranges of weight partition (from 5 to 50 kg). The new dosing strategy shows good rates of success (from 68 to 81%) between the ranges of weight, except for the very young patients (5-10 kg) where the success rate dropped to 54%.
Conversely, the standard dosing strategies yielded less homogeneous and more variable results (success rate ranging from 25 to 78%) between the different ranges of weight.
Discussion
This PPK analysis was carried out on a representative population of 24 PEDS treated with a classical Bu/Cy4 regimen for various malignant and nonmalignant diseases. PK data were obtained from children covering a wide span of age (from 0.45 to 16.7 years), with 13 patients aged from 0.45 to 4 years (median ¼ 1.6 years) and 11 patients aged from 4 to 16.7 years (median ¼ 10.7 years), representing a well-balanced distribution around the cutoff age of 4 years. From the studied population, the clearance of i.v. Bu demonstrated a low intrapatient variability (CV ¼ 9%) between doses 1, 9 and 13. This low intrapatient variation observed in pediatrics was consistent with the data observed in adults treated with either the same i.v. formulation of Bu 32 or a different i.v. form. 33 Recently, Hassan et al 34 demonstrated a low intrapatient variability when using an i.v. liposomal formulation in PEDS.
Nonlinear relationships between i.v. Bu PK and the patient body size best contributed to explain the interpatient variability. Vc was an allometric function of ABW and Cl tot was a log-linear function of either BSA or ABW. Both body size measurements yielded a similar performance to explain the interpatient changes of the clearance values. ABW was chosen instead of BSA, for the following three reasons :
(1) While dosing based on mg/m 2 might be preferred for several anticancer drugs, clinical experience indicates that errors in measuring height or length (particularly in younger children and infants) are common. 35 (2) Concerns have been expressed in a number of publications that PEDS may be receiving inappropriate doses because of inadequate method for the estimation of BSA and lack of standardization of methods between study centers. Large number of formulae to estimate BSA from children's height and weight are used. 31, [36] [37] [38] [39] [40] Some formulae such as Dubois and Dubois 36 are estimated from a small number of patients and serious errors in its use have been described. 41 (3) The adult dosing is commonly used on an mg/kg basis.
Therefore, a direct measure of patient body size such as the ABW is considered preferable and remains consistent with the adult dosing.
More importantly, modeling both Cl tot and Vd as a nonlinear function of patient body size demonstrated that age had no effect and did not explain the interpatient variability. These body size-based models avoided the determination of any break points of age that are likely to vary, depending on the set of the studied pediatric data.
The nomogram proposes five fixed doses (ranging from 0.8 to 1.2 mg/kg), which vary according to a given weight category. The higher doses of 1.2 to 1.1 mg/kg are dedicated to the young children belonging to the 9-16 and 16-23 kg weight groups, respectively. These doses are 38-50% higher than the ones given to adults (0.8 mg/kg).
This dosing guideline is in accordance with the knowledge on oral Bu that demonstrated approximately a 35-50% under-dosing in these groups of patients when receiving the same dose as the adults on an mg/kg basis. 10, 25, 26 Very young children (o1 year old) are difficult to recruit in BMT trials. Three patients below 1 year old and four patients below 9 kg (range: 7.1-8.5 kg) were included in our retrospective analysis. More data would be required to support the dosing in the very young patients (o9 kg). Furthermore, the absence of data for patients o7.1 kg limited the extrapolation of the model. Therefore, special caution should be considered to interpret the model curve dosing in the very young patients.
We adopted a conservative approach for the weight group o9 kg with a dosing of 1 mg/kg. This proposed dosing for the patients o9 kg was the same as performed during the clinical trial where all patients o4 years old and therefore patients o9 kg received 1 mg/kg on their first administration. In addition, it corresponds to the current dosing practice with oral Bu (1.2 mg/kg).
The modification of clearance rate is likely to be very rapid and dependent on multiple maturation factors involved in infants. Therefore, variation in the patient body size is probably not sufficient to account for the rapid process of hepatic maturation in the very young children (o1 year old). Besides, rapid alterations in the volume of distribution from changes in the proportion of body fat and body water might affect the PK disposition of Bu in infants.
The simulation analysis demonstrated that a fixed dose of 1 mg/kg enabled 54% of the younger patients (o10 kg) to achieve the target AUC (Figure 4 ). In this nomogram, for the patients with an ABW greater than 23 kg, progressively reduced doses from 0.95 to 0.8 mg/kg are given. The last nomogram weight group (434 kg), corresponding to pre-and adolescent patients, receives the same dose as for the adults. For such children, the hepatic maturation is likely to be completed and is probably not very different from the adult patient.
The new nomogram dosing is in agreement with the findings of Dupuis et al 42 who investigated oral Bu in 38 PEDS (aged from 0.17 to 17.5 years) very similar to the population we studied. The authors found that four fixed doses of oral Bu on an mg/m 2 basis were necessary to target the patient AUC (1300 mM min) (range: 900-1400 mM min). A similar tendency for oral dosing strategy was observed: the authors suggested higher doses for younger patients (35 and 45 mg/m 2 for patients o1 year old and between 1 and 5 years old, respectively) and progressively reduced doses for older patients (30 and 25 mg/m 2 for patients between 5-12 years and 412 years old, respectively).
The simulation analysis showed that a single fixed dose of 24 mg/m 2 produced comparable median exposure to the new dosing strategy, although resulting in higher variability (CV ¼ 36 vs 26%), and any fixed dose on an mg/m 2 basis was unable to maintain the same success rate in different weight groups (Figure 4 ). This last result supports the findings of several studies, 9, 23, 24 which confirmed that a single fixed dose of oral Bu on a mg/m 2 basis (480 or 600 mg/m 2 ) provides the same exposure as the adults but does not consistently reduce the large interpatient variability in drug exposure. The reported CV in AUC ranged from 37 to 47% when oral Bu was given on an mg/m 2 basis. The authors conclude that a more individualized oral Bu dosage in PEDS is required.
In order to replace the previous empirical age-based dosing, a new dosing strategy for i.v. Bu optimizing the dose by weight categories is proposed.
It is based on a rational development of an equation and is supported by the previous knowledge on oral Bu. Thanks to a reduced intraindividual variability, this new i.v. dosing strategy is expected to target the therapeutic AUC as soon as the first administration and maintain this target all along the Bu treatment without any dose adjustments, at least in the oldest children (X10 kg). Since this new dosing regimen is based on a retrospective analysis, a prospective study is ongoing to confirm the benefits in terms of PK variability, efficacy and safety.
PEDS are still under recruitment in each stratum of weight. The study preliminary data show encouraging results. 
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